Business Context and Reporting Period
This Form 8-K was filed by MedTech Acquisition Corporation, a special purpose acquisition company, regarding events occurring on June 12 and June 15, 2023. The filing relates to the extension of MedTech’s deadline to complete its proposed business combination with TriSalus Life Sciences, Inc. The filing text identifies MedTech as the registrant, not TriSalus.
Key Financial and Capitalization Matters
- Stockholders approved extending the business-combination deadline from June 22, 2023 to September 22, 2023, or an earlier date determined by the board.
- Stockholders holding 808,628 public shares elected redemption. Approximately $8.48 million, or approximately $10.49 per share, was expected to be withdrawn from the trust account.
- Approximately $12.00 million was expected to remain in the trust account after the redemptions.
- Following the redemptions, 1,144,794 public shares remained outstanding.
- MedTech agreed to deposit $0.04 per public share per month, beginning June 23, 2023, into the trust account during the extension period.
- The company issued its sponsor a non-interest-bearing Extension Note for up to $137,375.28. The note is repayable in full upon consummation of the initial business combination.
- MedTech expected to deposit $45,791.76 into the trust account, with 50% funded under the Extension Note and 50% funded by TriSalus pursuant to the November 11, 2022 merger agreement.
Material Changes and Approved Amendments
- The charter was amended to extend the business-combination deadline.
- The charter was amended to permit increases or decreases in authorized common or preferred shares, subject to specified limitations and voting requirements.
- Holders of Class B founder shares received the right to convert those shares into Class A common stock on a one-for-one basis before the business combination, at the holder’s option.
- The charter limitation prohibiting redemptions that would reduce net tangible assets below $5,000,001 was eliminated.
- All four proposals were approved. Of 7,497,322 shares represented at the meeting, the extension proposal received 6,333,932 votes for and 1,163,390 against.
Outlook, Risks, and Unusual Items
The extension provides additional time to complete the business combination but does not assure that the transaction will close. Continued extension funding, trust-account balances, shareholder redemptions, and the sponsor note affect the funds available for the transaction.
The removal of the $5,000,001 net-tangible-asset redemption limitation may permit additional redemptions and could reduce the capital available at closing. The filing does not provide operating revenue, profit, cash-flow, margin, or debt metrics for TriSalus or MedTech beyond the Extension Note and trust-account information.
Important Facts for Investors to Verify
- Whether the MedTech-TriSalus business combination was completed by the extended deadline.
- The final number of redeemed shares and the actual trust-account balance after redemptions and extension deposits.
- The amount ultimately funded by TriSalus and the sponsor under the extension arrangements.
- The terms, repayment status, and any subsequent amendments to the Extension Note.
- The filing’s date references: the stockholder meeting occurred on June 12, 2023, while the Extension Note and filing signature are dated June 15, 2023.